title: Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination.
abstract: BACKGROUND
  Data on the current burden of adenocarcinoma (ADC) and histology-specific human papillomavirus (HPV) type distribution are relevant to predict the future impact of prophylactic HPV vaccines.
  
  
  METHODS
  We estimate the proportion of ADC in invasive cervical cancer, the global number of cases of cervical ADC in 2015, the effect of cervical screening on ADC, the number of ADC cases attributable to high-risk HPV types -16, -18, -45, -31 and -33, and the potential impact of HPV vaccination using a variety of data sources including: GLOBOCAN 2008, Cancer Incidence in Five Continents (CI5) Volume IX, cervical screening data from the World Health Organization/Institut Català d'Oncologia Information Centre on HPV and cervical cancer, and published literature.
  
  
  RESULTS
  ADC represents 9.4% of all ICC although its contribution varies greatly by country and region. The global crude incidence rate of cervical ADC in 2015 is estimated at 1.6 cases per 100,000 women, and the projected worldwide incidence of ADC in 2015 is 56,805 new cases. Current detection rates for HPV DNA in cervical ADC tend to range around 80-85%; the lower HPV detection rates in cervical ADC versus squamous cell carcinoma may be due to technical artefacts or to misdiagnosis of endometrial carcinoma as cervical ADC. Published data indicate that the five most common HPV types found in cervical ADC are HPV-16 (41.6%), -18 (38.7%), -45 (7.0%), -31 (2.2%) and -33 (2.1%), together comprising 92% of all HPV positive cases. Future projections using 2015 data, assuming 100% vaccine coverage and a true HPV causal relation of 100%, suggest that vaccines providing protection against HPV-16/18 may theoretically prevent 79% of new HPV-related ADC cases (44,702 cases annually) and vaccines additionally providing cross-protection against HPV-31/33/45 may prevent 89% of new HPV-related ADC cases (50,769 cases annually).
  
  
  CONCLUSIONS
  It is predicted that the currently available HPV vaccines will be highly effective in preventing HPV-related cervical ADC.
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Pimenta
authors.forename: Claudia
authors.initials: C
authors.lastname: Galindo
authors.forename: David
authors.initials: D
authors.lastname: Jenkins
authors.affiliation: GlaxoSmithKline Vaccines, Avenue Fleming 20, B-1300, Wavre, Belgium. sylvia.m.taylor@gsk.com.
authors.forename: Sylvia M
authors.initials: SM
authors.lastname: Taylor
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*; D000367:Age Factors; D005260:Female; D014943:Global Health; D006801:Humans; D015994:Incidence; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics / Q000276:immunology; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control*; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines